Rhino 7 Platinum 3000, Single Blister Packs, distributed By Rhino 7, Made in USA
Published February 24, 2016 · Recall initiated: October 1, 2015
Summary
FDA records drug Class I recall D-0671-2016, published February 24, 2016 and initiated October 1, 2015. Recalling firm: MSNV, Inc dba National Video Supply; Status: Terminated; Reported quantity: 460 Blister Packs; Lot: All Lots. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- MSNV, Inc dba National Video Supply
- Distributor
- Nationwide
- Lot
- All Lots
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDARhino 7 3000, 6 count bottles, Distributed by Rhino 7, Made in USA.February 24, 2016
- FDARhino 7 3000, 6 count Bottle, Distributed by Rhino 7, Made in USAFebruary 24, 2016
- FDAVitamin Supplement (Vial) D3, (cholecalciferol (vit D3)/lipoic acid/ubiquinol/February 24, 2016
- FDACITRULLINE (L) in 25 g, 100 g, 500 g and 1 kg plastic bottles, White crystals or crystalline powder, odorless,February 24, 2016
- FDAMagnesium Sulfate in Water for Injection, (0.325 mEq Mg++/mL) 40 mg/mL, 2 g Total, 50 mL Single-Dose ContainerFebruary 24, 2016
- FDANATUREAL BURN FAT NATURE, 30-count capsules, packaged in clear plastic bottle, Manufactured for: Inaffit, LLC.February 24, 2016
Questions about this recall
Was Rhino 7 Platinum 3000, Single Blister Packs, distributed By Rhino 7, Made in USA recalled?
Yes. FDA published recall D-0671-2016 on February 24, 2016. Reported hazard: Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
What should I do if I have this product?
Voluntary: Firm initiated · Letter